• Home
  • About
      • Back
      • About Us
      • Management Team
      • Board of Directors
      • Clinical Advisors
      • Factsheet
  • Pipeline
      • Back
      • Pipeline
      • VDA-1102 Ointment
      • VDA-1102 IV
      • VDA-1275
  • Therapeutic Areas
      • Back
      • Oncology
          • Back
          • Solid Tumors
          • Cutaneous T-Cell Lymphoma (CTCL)
      • Dermatology
          • Back
          • Skin Cancer
          • Cutaneous Squamous Cell Carcinoma (cSCC)
          • Actinic Keratosis
  • Clinical Trials
      • Back
      • VDA-1102 Ointment
      • VDA 1102 CTCL
  • Technology
      • Back
      • HK2 in Cancer
      • VDAC/HK2
      • VDAC/HK2 Modulators
      • Immuno-Metabolism
  • News & Events
      • Back
      • Press Releases
      • Events
      • Publications
      • Factsheet
  • Contact

Pipeline

Vidac has built a portfolio of novel product candidates that target significant unmet medical needs in oncology and dermatology.

read more

News

VIDAC PHARMA ANNOUNCES INCLUSION OF THE FIRST PATIENT IN A PLACEBO CONTROLLED PHASE II STUDY

VIDAC PHARMA ANNOUNCES PUBLICATION OF A PEER REVIEWED ARTICLE ON VDA-1102 MECHANISM OF ACTION

VIDAC PHARMA TO PRESENT A POSTER AT THE SITC 2018 MEETING

VIDAC PHARMA ANNOUNCES INITIATION OF PHASE 2B CLINICAL TRIAL OF VDA-1102 OINTMENT IN PATIENTS WITH ACTINIC KERATOSIS

ABOUT

Vidac is a clinical stage innovative biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and dermatologic medical conditions.

CONTACT

Vidac Pharma
Weizmann Science Park
Einstein 18
PO Box 4053
Ness Ziona 7403622 Israel

FOLLOW

            
LiveSites | Login
© 2016 - 2021 Vidac
To Top